1. Home
  2. KUKE vs EQ Comparison

KUKE vs EQ Comparison

Compare KUKE & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KUKE
  • EQ
  • Stock Information
  • Founded
  • KUKE 2002
  • EQ 2017
  • Country
  • KUKE China
  • EQ United States
  • Employees
  • KUKE N/A
  • EQ N/A
  • Industry
  • KUKE Other Consumer Services
  • EQ Biotechnology: Pharmaceutical Preparations
  • Sector
  • KUKE Real Estate
  • EQ Health Care
  • Exchange
  • KUKE Nasdaq
  • EQ Nasdaq
  • Market Cap
  • KUKE 21.2M
  • EQ 24.8M
  • IPO Year
  • KUKE 2021
  • EQ 2018
  • Fundamental
  • Price
  • KUKE $0.48
  • EQ $0.64
  • Analyst Decision
  • KUKE
  • EQ Buy
  • Analyst Count
  • KUKE 0
  • EQ 2
  • Target Price
  • KUKE N/A
  • EQ $5.00
  • AVG Volume (30 Days)
  • KUKE 799.4K
  • EQ 141.5K
  • Earning Date
  • KUKE 01-31-2025
  • EQ 11-13-2024
  • Dividend Yield
  • KUKE N/A
  • EQ N/A
  • EPS Growth
  • KUKE N/A
  • EQ N/A
  • EPS
  • KUKE N/A
  • EQ N/A
  • Revenue
  • KUKE $14,784,158.00
  • EQ $45,914,000.00
  • Revenue This Year
  • KUKE N/A
  • EQ $4.76
  • Revenue Next Year
  • KUKE N/A
  • EQ N/A
  • P/E Ratio
  • KUKE N/A
  • EQ N/A
  • Revenue Growth
  • KUKE 10.48
  • EQ 7.70
  • 52 Week Low
  • KUKE $0.23
  • EQ $0.56
  • 52 Week High
  • KUKE $4.07
  • EQ $3.25
  • Technical
  • Relative Strength Index (RSI)
  • KUKE 53.14
  • EQ 39.10
  • Support Level
  • KUKE $0.39
  • EQ $0.64
  • Resistance Level
  • KUKE $0.50
  • EQ $0.73
  • Average True Range (ATR)
  • KUKE 0.10
  • EQ 0.08
  • MACD
  • KUKE 0.00
  • EQ -0.00
  • Stochastic Oscillator
  • KUKE 27.29
  • EQ 10.12

About KUKE Kuke Music Holding Limited

Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.

About EQ Equillium Inc.

Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Share on Social Networks: